Wedbush reiterated their outperform rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a report released on Monday morning. Wedbush currently has a $4.00 price target on the biopharmaceutical company’s stock. Wedbush also issued estimates for Regulus Therapeutics’ FY2017 earnings at ($0.95) EPS, Q2 2018 earnings at ($0.11) EPS, Q3 2018 earnings at ($0.11) EPS, Q4 2018 earnings at ($0.11) EPS, FY2018 earnings at ($0.46) EPS, FY2019 earnings at ($0.48) EPS, FY2020 earnings at ($0.56) EPS and FY2021 earnings at ($0.21) EPS.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of Regulus Therapeutics from a buy rating to a hold rating in a research report on Tuesday, September 19th. Needham & Company LLC reaffirmed a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus price target of $2.60.

Regulus Therapeutics (NASDAQ RGLS) opened at $0.90 on Monday. Regulus Therapeutics has a 12-month low of $0.79 and a 12-month high of $2.75. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77.

Several hedge funds have recently made changes to their positions in RGLS. Quantitative Investment Management LLC bought a new stake in shares of Regulus Therapeutics during the 2nd quarter worth about $103,000. GSA Capital Partners LLP bought a new stake in Regulus Therapeutics in the 2nd quarter valued at about $139,000. LMR Partners LLP bought a new stake in Regulus Therapeutics in the 2nd quarter valued at about $164,000. Royal Bank of Canada boosted its holdings in Regulus Therapeutics by 12.1% in the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 19,934 shares during the period. Finally, Wedbush Securities Inc. boosted its holdings in Regulus Therapeutics by 10.3% in the 2nd quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after purchasing an additional 18,600 shares during the period. 59.41% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/15/regulus-therapeutics-rgls-receives-outperform-rating-from-wedbush.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Stock Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related stocks with our FREE daily email newsletter.